Advertisement

Topics

Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

14:49 EDT 25th May 2016 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 18,000+

Extremely Relevant

Cyramza indication extended

The indication of Cyramza (ramucirumab; Eli Lilly), in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), has been extended to include the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. In addition, Cyramza in combination with docetaxel is also indicated ...


Merrimack, Baxalta initiate phase I study of MM-151 for colorectal cancer

Merrimack Pharmaceuticals and Baxalta are initiating a phase I clinical study of Merrimack’s oligoclonal EGFR (epidermal growth factor receptor) inhibitor, MM-151, in combination with ONIVYDE (irinotecan liposome injection) plus fluorouracil (5-FU) and leucovorin in patients with RAS wild-type metastatic colorectal cancer. Data from a prior phase I study of MM-151 supports further clinical e...

Colorectal cancer patients need colonoscopy after cancer resection

(American Gastroenterological Association) It is critically important that colorectal cancer patients undergo colonoscopy after surgery to ensure that they do not have a second colon cancer, and to find and remove any additional polyps. According to new recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer, the evidence shows that post-operative colonoscopy is associated with...


Merrimack begins Phase l combination trial of MM-151 and onivyde to treat metastatic colorectal cancer

Merrimack Pharmaceuticals, along with Baxalta, has begun a Phase l clinical trial of MM-151 in combination with onivyde (irinotecan liposome injection), fluorouracil (5-FU) and leucovorin to treat RAS wild-type, metastatic, colorectal cancer patients…

Colorectal Cancer: Year in Review

After several years of exciting developments in colorectal cancer research and therapy, progress continued throughout 2015. The FDA approved a new drug to treat colorectal cancer, and much research has been done with combination therapies and protocols for treatment. Of great importance, research shows that when colorectal cancer is detected during a screening colonoscopy, patients […] The p...

Colorectal cancer more likely to affect minorities at younger age

(University of Missouri-Columbia) Colorectal cancer is the third most common form of cancer and the second most common cause of cancer deaths in the United States. The chance of developing colorectal cancer increases with age. Now, a study by University of Missouri School of Medicine researchers shows that minority and ethnic groups are being diagnosed with colorectal cancer at younger ages and mo...

Merrimack and Baxalta announce initiation of Phase I study of MM-151 in combination with ONIVYDE regimen in metastatic colorectal cancer

Merrimack Pharmaceuticals and Baxalta jointly announced the initiation of a Phase I clinical study of Merrimack's oligoclonal EGFR (epidermal growth factor receptor) inhibitor, MM-151, in combination with ONIVYDE® (irinotecan liposome injection) plus fluorouracil (5-FU) and leucovorin in patients with RAS wild-type metastatic colorectal cancer.

New potential treatment for colorectal cancer discovered

A small molecule drug combined with chemotherapy may deliver a synergistic benefit for colorectal cancer patients, new research suggests. has demonstrated the efficiency of a small molecule drug, PRIMA-1met, in inhibiting the growth of colorectal cancer cells. Colorectal cancer is the cancer of the large intestine (colon and rectum).

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab

[Comment] Equal access to colorectal cancer screening

Population-based screening is effective in reducing the burden of colorectal cancer, and organised screening programmes have been implemented in many European countries.1 Maximum participation in screening is crucial to achieve the greatest health benefits at population level. As with most cancer screening programmes, however, there is a gradient in uptake of colorectal cancer screening by socioec...

Colorectal cancer stemness and ERK

Colorectal cancer stemness and ERK Larry H. Bernstein, MD, FCAP, Curator LPBI   KCTD12 Regulates Colorectal Cancer Cell Stemness through the ERK Pathway Liping Li, Tingmei Duan, Xin Wang, Ru-Hua Zhang, Meifang Zhang, Suihai Wang,Fen Wang, Yuanzhong Wu, Haojie Huang & Tiebang Kang Scientific Reports 2016; 6(20460)    http://dx.doi.org:/10.1038/srep20460 Targeting cancer stem cells (CSC...

Merck’s Erbitux approved for NHS Wales

The All Wales Medicines Strategy Group has recommended Merck’s Erbitux in combination with chemotherapy for restricted use in the NHS in Wales. Erbitux (cetuximab) is recommended for the first-line treatment of patients with RAS wild-type metastatic colorectal cancer. Its full indication is with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in com...

Relevant

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated for individuals at an average risk of developing colorectal cancer who choose not to undergo other colorectal cancer screening methods specified in […] The post EPI proColon® – N...

Cancer-Suppressing Gene May Cause Colorectal Cancer Spread

University of Missouri School of Medicine researchers discovered that a cancer-suppressing gene called Sprouty2 may induce the growth of certain forms of colorectal cancer. It was previously shown that the gene has a protective role against tumor metastasis in the body, according to the university’s press release.

Microbiota profiles in patients with colorectal cancer differ from healthy individuals

Microbiota profiles associated with colorectal cancer were found to be different from those in individuals without colorectal cancer in a recent study. Moreover, bacterial clusters associated with colorectal cancer were found to be differentially correlated with mucosal gene-expression profiles. “The heterogeneity of the CRC-associated microbiota identified could be exploited as a screening tool...

Researchers Discover Colorectal Cancer Biomarker

UNC Lineberger Comprehensive Cancer Center researchers have discovered that a deficiency in a key protein that regulates immune system warning signals could be a new biomarker for colorectal cancer, the second largest cancer killer in the United States. They believe the marker could be used to gauge response to a potential new treatment for the disease.Read more about Researchers Discover Colorect...

Small molecule drug combined with chemotherapy may deliver a synergistic benefit for colorectal cancer patients

A study led by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has demonstrated the efficiency of a small molecule drug, PRIMA-1met, in inhibiting the growth of colorectal cancer cells. Colorectal cancer is the cancer of the large intestine (colon and rectum) and is the most common cancer in Singapore.

Using Bevacizumab in High-Risk Cervical Cancer

Dr Maurie Markman discusses a paper showing that bevacizumab significantly improves overall survival rates in high-risk cervical cancer patients. Medscape Oncology

Gene thought to suppress cancer may actually promote spread of colorectal cancer

(University of Missouri-Columbia) A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer, University of Missouri School of Medicine researchers have found. It is a finding that may lay the foundation for new colorectal cancer treatments.

No matter how you take it, coffee drinking can decrease the risk of colorectal cancer says new study

To carry out their study, researchers at the University of Southern California (USC) looked at a group of 5,145 participants with colorectal cancer, and a further 4,097 participants without colorectal cancer as a control group. Data on coffee consumption was collected by interview and

Oophorectomy may increase colorectal cancer risk

Women who underwent oophorectomy for benign indications appeared at greater risk for colorectal cancer, according to the results of a population study conducted in Sweden.Data have shown that hormonal factors may influence the development of colorectal cancer, according to study background.

We met the Biotech with the First & Only US Approved Blood Test for Colorectal Cancer

Colorectal cancer is the second biggest Cancer killer in the US. This sad figure could be dramatically improved. A problem Berlin-based Epigenomics want to solve and just got a significant milestone: an FDA approval for commercialisation. I met with Thomas Taapken, the CEO of ... This awesome article We met the Biotech with the First & Only US Approved Blood Test for Colorectal Cancer app...

Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications

In a little over the past year, several clinical trials have evaluated new drugs in patients with metastatic colorectal cancer and gastric cancer. Furthermore, genomics studies that attempted to unravel the molecular characteristics of colorectal and gastric cancer were published in 2015. The results of these endeavours will influence clinical practice in 2016 and beyond.

LabCorp Launches Colorectal Cancer Test, But Key Hurdles Remain

The market for colorectal cancer tests that are less cumbersome than colonoscopies is getting more crowded. LabCorp announced the launch of a blood-based colorectal cancer test on Monday, which will pit it against other makers of non-invasive diagnostics for such diseases, including Madison, WI-based Exact Sciences (NASDAQ: EXAS). Burlington, NC-based LabCorp (NYSE: LH) has worked […]

Research points to why some colorectal cancers recur after treatment

(University of Texas M. D. Anderson Cancer Center) Cetuximab, marketed as Erbitux, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival.


Quick Search
Advertisement
 

News Quicklinks